News/Publications
Ibrutinib in previously treated Waldenström´s macroglobulinemia.
Treon SP1, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL,Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Dimopoulos MA1, Kastritis E1, Owen RG2, Kyle RA3, Landgren O4, Morra E5, Leleu X6, García-Sanz R7, Munshi N8, Anderson KC8, Terpos E1, Ghobrial IM8,Morel P9, Maloney D10, Rummel M11, Leblond V12, Advani RH13, Gertz MA3, Kyriakou C14, Thomas SK15, Barlogie B16, Gregory SA17, Kimby E18, Merlini G19,Treon SP8.
Clinical Intergroup
Clinical Intergroup
The ECWM is based on a clinical intergroup connecting all major clinical national study groups such as:
- BNLI
- Czech Myeloma Group
- FIL Italian Intergroup
- FCGCLLWM Group
- GLSG/OSHO
- Greek Myeloma Study Group
- HOVON
- Nordic Lymphoma Group
- Portuguese Lymphoma Study Group
- Spanish Study Group
This clinical intergroup forms a unique platform for setting up large clinical and innovative trials in a rare disease such as WM.
Currently several clinical trials are initiated which offer patients with WM novel therapeutic approaches in the setting of well controlled clinical trials.